Daily News Podcast

New cell-free DNA assays hold promise for lung cancer screening


 

A set of blood-based assays that search for abnormalities in cell-free DNA show moderately good sensitivity for detecting early-stage lung cancer. Also today, the FDA approves rituximab for the treatment of pemphigus vulgaris (prescribing information), obstructive sleep apnea with worsening hypoxemia raises metabolic syndrome risk, and the Department of Justice won’t defend the Affordable Care Act from a lawsuit. Listen to the MDedge Daily News podcast for all the details on today’s top news.

Recommended Reading

TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
MDedge Rheumatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Rheumatology
Hip pain predicts arthritis mortality beyond comorbidities
MDedge Rheumatology
Prostate cancer risk before age 55 higher for black men
MDedge Rheumatology
Statin effect in prostate cancer may be caused by reduced inflammation
MDedge Rheumatology
Raised LDL cholesterol, hsCRP tied to polymyalgia rheumatica, GCA
MDedge Rheumatology
Smoking tied to localized prostate cancer recurrence, metastasis, death
MDedge Rheumatology
FDA approves rituximab for treating pemphigus vulgaris
MDedge Rheumatology
EMEUNET network of young rheumatologists keeps moving forward
MDedge Rheumatology
Suicide rate jumps 30%
MDedge Rheumatology